127 related articles for article (PubMed ID: 38350067)
21. Phase I Trial of
D'Huyvetter M; Vos J; Caveliers V; Vaneycken I; Heemskerk J; Duhoux FP; Fontaine C; Vanhoeij M; Windhorst AD; Aa FV; Hendrikse NH; Eersels JLE; Everaert H; Gykiere P; Devoogdt N; Raes G; Lahoutte T; Keyaerts M
J Nucl Med; 2021 Aug; 62(8):1097-1105. PubMed ID: 33277400
[No Abstract] [Full Text] [Related]
22. Evaluation of Safety, Biodistribution, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog 177 Lu-DOTA-EB-TATE With and Without Amino Acid Infusion.
Jiang Y; Liu Q; Wang G; Zhang J; Zhu Z; Chen X
Clin Nucl Med; 2023 Jun; 48(6):e289-e293. PubMed ID: 37075254
[TBL] [Abstract][Full Text] [Related]
23. A preliminary clinical trial to evaluate
Lee I; Lim I; Byun BH; Kim BI; Choi CW; Woo SK; Kim KI; Lee KC; Kang JH; Seong MK; Kim HA; Noh WC; Lim SM
EJNMMI Res; 2021 Jan; 11(1):8. PubMed ID: 33475899
[TBL] [Abstract][Full Text] [Related]
24. Dosimetry of
Violet J; Jackson P; Ferdinandus J; Sandhu S; Akhurst T; Iravani A; Kong G; Kumar AR; Thang SP; Eu P; Scalzo M; Murphy D; Williams S; Hicks RJ; Hofman MS
J Nucl Med; 2019 Apr; 60(4):517-523. PubMed ID: 30291192
[No Abstract] [Full Text] [Related]
25. Biodistribution and Dosimetry Results from a Phase 1 Trial of Therapy with the Antibody-Radionuclide Conjugate
Blakkisrud J; Holtedahl JE; Løndalen A; Dahle J; Bach-Gansmo T; Holte H; Nygaard S; Kolstad A; Stokke C
J Nucl Med; 2018 Apr; 59(4):704-710. PubMed ID: 28848035
[No Abstract] [Full Text] [Related]
26.
Santos-Cuevas C; Ferro-Flores G; García-Pérez FO; Jiménez-Mancilla N; Ramírez-Nava G; Ocampo-García B; Luna-Gutiérrez M; Azorín-Vega E; Davanzo J; Soldevilla-Gallardo I
Contrast Media Mol Imaging; 2018; 2018():5247153. PubMed ID: 30534027
[TBL] [Abstract][Full Text] [Related]
27. Prostate-Specific Membrane Antigen Radioligand Therapy Using
Schuchardt C; Zhang J; Kulkarni HR; Chen X; Müller D; Baum RP
J Nucl Med; 2022 Aug; 63(8):1199-1207. PubMed ID: 34887335
[TBL] [Abstract][Full Text] [Related]
28. Pretherapeutic Comparative Dosimetry of
Feuerecker B; Chantadisai M; Allmann A; Tauber R; Allmann J; Steinhelfer L; Rauscher I; Wurzer A; Wester HJ; Weber WA; d'Alessandria C; Eiber M
J Nucl Med; 2022 Jun; 63(6):833-839. PubMed ID: 34531260
[TBL] [Abstract][Full Text] [Related]
29. A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu.
Konijnenberg MW; Bijster M; Krenning EP; De Jong M
J Nucl Med; 2004 Jul; 45(7):1260-9. PubMed ID: 15235075
[TBL] [Abstract][Full Text] [Related]
30. Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC.
Wehrmann C; Senftleben S; Zachert C; Müller D; Baum RP
Cancer Biother Radiopharm; 2007 Jun; 22(3):406-16. PubMed ID: 17651048
[TBL] [Abstract][Full Text] [Related]
31. Biodistribution and dosimetry of
Li H; Pei W; Yang X; Qu G; Hua Q; Liu L; Wang Y; Xu T; Chen Y
EJNMMI Res; 2024 Mar; 14(1):30. PubMed ID: 38517637
[TBL] [Abstract][Full Text] [Related]
32. Gadolinium-Based Nanoparticles Sensitize Ovarian Peritoneal Carcinomatosis to Targeted Radionuclide Therapy.
Garcia-Prada CD; Carmes L; Atis S; Parach A; Bertolet A; Jarlier M; Poty S; Garcia DS; Shin WG; Du Manoir S; Schuemann J; Tillement O; Lux F; Constanzo J; Pouget JP
J Nucl Med; 2023 Dec; 64(12):1956-1964. PubMed ID: 37857502
[TBL] [Abstract][Full Text] [Related]
33. Assessment of absorbed dose for Zr-89, Sm-153 and Lu-177 medical radioisotopes: IDAC-Dose2.1 and OLINDA experience.
Mostafa MYA; Zakaly HMH; Tekin HO; Issa SAM; Erdemir RU; Zhukovsky M
Appl Radiat Isot; 2021 Oct; 176():109841. PubMed ID: 34214913
[TBL] [Abstract][Full Text] [Related]
34. Indium-111-DOTA-lanreotide: biodistribution, safety and radiation absorbed dose in tumor patients.
Virgolini I; Szilvasi I; Kurtaran A; Angelberger P; Raderer M; Havlik E; Vorbeck F; Bischof C; Leimer M; Dorner G; Kletter K; Niederle B; Scheithauer W; Smith-Jones P
J Nucl Med; 1998 Nov; 39(11):1928-36. PubMed ID: 9829585
[TBL] [Abstract][Full Text] [Related]
35. Prediction of Normal Organ Absorbed Doses for [177Lu]Lu-PSMA-617 Using [44Sc]Sc-PSMA-617 Pharmacokinetics in Patients With Metastatic Castration Resistant Prostate Carcinoma.
Khawar A; Eppard E; Sinnes JP; Roesch F; Ahmadzadehfar H; Kürpig S; Meisenheimer M; Gaertner FC; Essler M; Bundschuh RA
Clin Nucl Med; 2018 Jul; 43(7):486-491. PubMed ID: 29688951
[TBL] [Abstract][Full Text] [Related]
36. Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer.
Kabasakal L; AbuQbeitah M; Aygün A; Yeyin N; Ocak M; Demirci E; Toklu T
Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1976-83. PubMed ID: 26227531
[TBL] [Abstract][Full Text] [Related]
37. Clinical implementation of PLANET® Dose for dosimetric assessment after [
Santoro L; Pitalot L; Trauchessec D; Mora-Ramirez E; Kotzki PO; Bardiès M; Deshayes E
EJNMMI Res; 2021 Jan; 11(1):1. PubMed ID: 33394212
[TBL] [Abstract][Full Text] [Related]
38. Functional imaging of human epidermal growth factor receptor 2-positive metastatic breast cancer using (64)Cu-DOTA-trastuzumab PET.
Mortimer JE; Bading JR; Colcher DM; Conti PS; Frankel PH; Carroll MI; Tong S; Poku E; Miles JK; Shively JE; Raubitschek AA
J Nucl Med; 2014 Jan; 55(1):23-9. PubMed ID: 24337604
[TBL] [Abstract][Full Text] [Related]
39. High-dose radioimmunotherapy with 90Y-ibritumomab tiuxetan: comparative dosimetric study for tailored treatment.
Cremonesi M; Ferrari M; Grana CM; Vanazzi A; Stabin M; Bartolomei M; Papi S; Prisco G; Ferrucci PF; Martinelli G; Paganelli G
J Nucl Med; 2007 Nov; 48(11):1871-9. PubMed ID: 17978355
[TBL] [Abstract][Full Text] [Related]
40. Preclinical pharmacokinetics, biodistribution, radiation dosimetry and acute toxicity studies required for regulatory approval of a Clinical Trial Application for a Phase I/II clinical trial of (111)In-BzDTPA-pertuzumab.
Lam K; Chan C; Done SJ; Levine MN; Reilly RM
Nucl Med Biol; 2015 Feb; 42(2):78-84. PubMed ID: 25459109
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
